Business Wire

Merck and Ridgeback’s Investigational Oral Antiviral Molnupiravir Reduced the Risk of Hospitalization or Death by Approximately 50 Percent Compared to Placebo for Patients ...

KENILWORTH, N.J. & MIAMI--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics today announced that molnupiravir (MK-4482, EIDD-2801), ...
Business Wire

Ridgeback Biotherapeutics Announces Launch of Phase 2 Trials Testing EIDD-2801 as Potential Treatment for COVID-19

MIAMI--(BUSINESS WIRE)--Ridgeback Biotherapeutics announces the launch of two Phase 2 clinical trials to test the efficacy of EIDD-2801 as an anti-viral treatment for COVID-19. Phase 1 trials recently ...
Yahoo Finance

Emergent BioSolutions and Ridgeback Biotherapeutics Enter Into Agreement for Ebanga™ Treatment for Ebola

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
FiercePharma

Emergent inks deal to manufacture and sell Ridgeback's Ebola drug in the US

A partnership between the U.S. government’s Biomedical Advanced Research and Development Authority (BARDA) and Ridgeback Biotherapeutics helped secure an FDA approval for Ebola treatment Ebanga back ...
Nasdaq

Merck and Ridgeback Biotherapeutics Provide Update on Results from MOVe-OUT Study of Molnupiravir, an Investigational Oral Antiviral Medicine, in At Risk Adults With Mild-to ...

KENILWORTH, N.J. & MIAMI--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics today provided an update on the MOVe-OUT study of ...
FiercePharma

With FDA nod, Ridgeback's Ebanga joins Regeneron's Inmazeb in the Ebola-fighting arsenal

Nearly seven years after the largest Ebola epidemic broke out in West Africa, two drugs against the deadly virus are now available. The FDA has approved Ridgeback Biotherapeutics’ Ebanga, or ansuvimab ...